Strong Top-Line Growth
Organic sales growth of 11.0% in Q4 and 10.3% for full-year 2025, with total sales surpassing $25 billion; U.S. full-year organic growth of 11.2% and international organic growth of 7.5%.
Segment Outperformance — MedSurg & Neurotechnology
MedSurg & Neurotechnology delivered exceptional Q4 organic growth of 12.6% (U.S. +13.0%, International +10.9%), driven by instruments, endoscopy, and medical product strength.
Instruments and Endoscopy Momentum
Instruments U.S. organic sales up 19.1% (high-teens growth across orthopedic instruments and Surgical Technologies); Endoscopy U.S. organic sales up 11.1% led by sustainability and sports medicine camera/platform adoption.
Robotics Leadership and Mako 4 Performance
Record quarter of Mako installations; installed base topped >3,000 worldwide. U.S. utilization: over two-thirds of knees and over one-third of hips on Mako; global utilization ~50% knees and >20% hips. New applications and Mako 4 drove strong adoption and utilization gains.
Orthopaedics Growth and New Product Momentum
Orthopaedics organic growth 8.4% (U.S. +9.6%, International +5.4%). Notable: U.S. knees +7.6%, U.S. hips +5.6%, Trauma & Extremities U.S. +8.5%, and U.S. Other ortho +28.7% driven by Mako 4 installations and recent launches (e.g., Triathlon Gold limited launch).
Earnings, Margin Expansion, and Profitability
Q4 adjusted EPS $4.47 (+11.5% YoY) and full-year adjusted EPS $13.63 (+11.8% YoY). Adjusted operating margin expanded to 30.2% (100 basis points improvement YoY); second consecutive year of ≥100 bps adjusted operating margin expansion.
Strong Cash Flow and Balance Sheet
Year-to-date cash from operations of $5.0 billion, up $820 million YoY; free cash flow as % of adjusted net earnings 81% vs 75% prior year (target range 70–80%). Management signals continued M&A firepower from strong financial position.
Constructive 2026 Guidance and Market Outlook
Provided 2026 guidance of organic net sales growth of 8.0%–9.5% and adjusted net EPS of $14.90–$15.10; management expects sustained procedural volumes, healthy hospital CapEx and an elevated capital order book entering 2026.